Clinical efficacy of paclitaxel combined with LFC regimen in the treatment of advanced gastric cancer
- Author:
Li SUN
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
5-fluorouracil;
Cisplatin;
Drug therapy, combination;
Paclitaxel;
Stomach neoplasms
- From:
Tumor
2007;27(7):582-584
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical efficacy of PFLC regimen (paclitaxel + 5-FU + cisplatin) on advanced gastric cancer patients and observe adverse effects and survival period. Methods: Twenty-four patients with advanced gastric cancer were treated with PLFC regimen (paclitaxel + Leucovorin + 5-FU + cisplatin). One cycle lasted for 21-28 d. The therapeutic efficacy was evaluated after 2 cycles chemotherapy. Results: The objective response rate for ali patients was 50%, with 8.33% of complete remission (CR), 41. 67% of partial remission (PR), 25% of stable disease (SD), and 25% progressive disease (PD). Higher efficacy was observed in patients without previous treatment than those with previous treatment, and in patients at III b stage compared with those at IV stage. Patients with higher KPS score had more favorable efficacy and better tolerance than those with lower KPS score. Myelosuppression (66.7%), gastrointestinal reactions (50%), and alopecia (41.67%) were the major adverse events. Conclusions: PLFC regimen can be used in treating advanced gastric for its identical therapeutic effects and good tolerance.
